- Home
- ENTA vs FSP Comparison
ENTA vs FSP Comparison
Compare ENTA & FSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- FSP
- Stock Information
- Founded
- ENTA 1995
- FSP 1981
- Country
- ENTA United States
- FSP United States
- Employees
- ENTA N/A
- FSP N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- FSP Real Estate Investment Trusts
- Sector
- ENTA Health Care
- FSP Real Estate
- Exchange
- ENTA Nasdaq
- FSP Nasdaq
- Market Cap
- ENTA 164.6M
- FSP 165.9M
- IPO Year
- ENTA 2013
- FSP N/A
- Fundamental
- Price
- ENTA $10.96
- FSP $1.20
- Analyst Decision
- ENTA Strong Buy
- FSP
- Analyst Count
- ENTA 5
- FSP 0
- Target Price
- ENTA $21.00
- FSP N/A
- AVG Volume (30 Days)
- ENTA 518.3K
- FSP 766.2K
- Earning Date
- ENTA 11-17-2025
- FSP 10-28-2025
- Dividend Yield
- ENTA N/A
- FSP 3.33%
- EPS Growth
- ENTA N/A
- FSP N/A
- EPS
- ENTA N/A
- FSP N/A
- Revenue
- ENTA $64,806,000.00
- FSP $109,497,000.00
- Revenue This Year
- ENTA $0.07
- FSP $4.36
- Revenue Next Year
- ENTA N/A
- FSP $0.81
- P/E Ratio
- ENTA N/A
- FSP N/A
- Revenue Growth
- ENTA N/A
- FSP N/A
- 52 Week Low
- ENTA $4.09
- FSP $1.19
- 52 Week High
- ENTA $15.34
- FSP $2.21
- Technical
- Relative Strength Index (RSI)
- ENTA 54.87
- FSP 15.01
- Support Level
- ENTA $10.30
- FSP $1.39
- Resistance Level
- ENTA $11.45
- FSP $1.42
- Average True Range (ATR)
- ENTA 0.62
- FSP 0.05
- MACD
- ENTA -0.12
- FSP -0.02
- Stochastic Oscillator
- ENTA 41.67
- FSP 3.33
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.